Pipeline Moves: Investigator-led trial of Lilly's merestinib in solid tumours terminated [Yahoo! Finance]
Leap Therapeutics, Inc. (LPTX)
Last leap therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.leaptx.com
Company Research
Source: Yahoo! Finance
Meanwhile, RevImmune terminated a Phase II trial of its Mycobacterium avium infection candidate CYT-107 and a Phase II investigator-led trial of Leap Therapeutics sirexatamab was terminated. On a positive note, Trellis Bioscience completed a Phase I trial of calpurbatug (TRL1068) in gram-positive and gram-negative bacterial infections. Investigator led trial of Lilly's merestinib terminated Eli Lilly's merestinib has seen its Phase Transition Success Rate (PTSR) drop after an investigator-led Phase II trial of the candidate in solid tumours was terminated. The PTSR for merestinib dropped in solid tumors by 15 points to 11%. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. The status of the trial which was being run by Dana-Farber Cancer Institute was changed from active, not recruiting to terminated on ClinicalTrials.gov on 11 April. GlobalData evaluated the asset on 12 April. The ClinicalTrials.gov l
Show less
Read more
Impact Snapshot
Event Time:
LPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LPTX alerts
High impacting Leap Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LPTX
News
- Leap Therapeutics, Inc. (NASDAQ: LPTX) had its price target lowered by analysts at HC Wainwright from $7.00 to $5.50. They now have a "buy" rating on the stock.MarketBeat
- Leap Therapeutics Reports First Quarter 2024 Financial ResultsPR Newswire
- Leap Therapeutics Announces $40 Million Private Placement [Yahoo! Finance]Yahoo! Finance
- Leap Therapeutics Announces $40 Million Private PlacementPR Newswire
- Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
LPTX
Earnings
- 3/18/24 - Beat
LPTX
Sec Filings
- 5/16/24 - Form DEFA14A
- 5/13/24 - Form 8-K
- 5/13/24 - Form 10-Q
- LPTX's page on the SEC website